Navigation Links
PharmAthene and Theraclone Sciences Announce Merger Agreement to Create Diversified Biologics Company Targeting Government and Commercial Markets
Date:8/1/2013

l head the new company, commented, "By combining PharmAthene's strong vaccine and biologics development capabilities and government contracting experience, with our clinical antibody candidates and novel discovery platform we are establishing a premier biologics organization with multiple product candidates possessing significant near- and longer-term revenue potential in high-value commercial markets."

Clinical Stage Product Pipeline

The combined company's clinical stage product candidates following the merger will include:

  • TCN-202 CMV Antibody – a broadly-neutralizing mAb that is being developed for the prevention and treatment of human cytomegalovirus (CMV) infections, common in immunocompromised populations, including patients with HIV, cancer and those undergoing organ transplant surgery. TCN-202 has completed a Phase 1 clinical trial, with a Phase 2 study in solid organ transplant scheduled to begin later this year.  The combined company will explore other indications for this program.
  • TCN-032 Influenza Antibody – a broadly-protective mAb being developed for the treatment of pandemic and severe seasonal influenza.  TCN-032 has completed a Phase 2a clinical trial, with results expected to be announced later this year.
  • SparVax® Anthrax Vaccine – a recombinant protective antigen (rPA), next-generation anthrax vaccine being developed for pre and post-exposure prophylaxis of anthrax infection.  One Phase 1 and two Phase 2 clinical trials involving 770 subjects have been completed.  Additional Phase 2 clinical trial testing is planned to begin this year.
  • Valortim® Anthrax Anti-Toxin – a fully human mAb intended for the prevention and treatment
    '/>"/>

SOURCE PharmAthene, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. PharmAthene Reports First Quarter 2013 Financial And Operational Results
2. New Data Show PharmAthenes Recombinant Bioscavenger Binds To A Broad Spectrum Of Chemical Nerve Agents
3. SIGA Technologies Files Notice of Appeal in PharmAthene Litigation
4. PurThread Technologies Welcomes Life Sciences Veterans to CEO and Board Positions
5. Earnings Releases, Investment Plans, Commencement of Clinical Trials, and FDA Applications Brighten Outlook - Research Report on Bard, Centene, Exact Sciences, Ironwood, and Merrimack
6. Thomson Reuters Life Sciences Cortellis Competitive Intelligence Reaches Content Milestones
7. Sangamo BioSciences Reports Second Quarter 2013 Financial Results
8. BioDelivery Sciences Announces the Hiring of Adrian Hepner, M.D. as Vice President of Clinical Research & Regulatory Affairs
9. MELA Sciences, Inc., A Leader In The Fight Against Melanoma, Hosts Symposium At 8th World Congress Of Melanoma
10. Sangamo BioSciences Announces Publication of First Demonstration of Inactivation of Extra Chromosome Responsible for Down Syndrome
11. Sangamo BioSciences Announces Second Quarter 2013 Conference Call And Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... , Aug. 29, 2014 The Competitive Intelligence ... and marketplace changes. CI leaders who adjust will succeed, ... In a new Best Practices, LLC study CI leaders ... insights, including: - Use secondary research whenever ... research - Internal staff who are creative ...
(Date:8/29/2014)...   Mast Therapeutics, Inc. (NYSE MKT: ... Santosh Vetticaden, Chief Medical Officer and Senior Vice ... reasons, in mid-September.  Edwin L. Parsley , ... which Mast acquired earlier this year, will assume ... Chief Medical Officer.  Dr. Parsley previously was with ...
(Date:8/29/2014)... Research and Markets has announced ... Report, 2014-2017" report to their offering. ... of reimbursement for medical expenses, the Chinese orthopedic instrument ... presenting a CAGR of 19.2% during 2009-2013. Trauma products, ... of orthopedic instruments in China , ...
Breaking Medicine Technology:Using the Competitive Intelligence Function to Drive Better Business Decisions in the Pharmaceutical Sector 2Mast Therapeutics Announces Management Change 2Mast Therapeutics Announces Management Change 3Mast Therapeutics Announces Management Change 4China Orthopedic Instrument Industry Report, 2014-2017 2
... - MIV Therapeutics Inc.,(OTCBB:MIVT) (FWB:MIV), a leading ... delivery systems for,cardiovascular stents and other implantable ... sponsored bench test confirmed that,merging Biosync Scientific's ... acquired, with the Company's polymer-free drug,delivery system ...
... to Company Oncology Programs to be Presented, SOUTH ... Incorporated announced,today that four posters containing non-clinical data ... the American Association,for Cancer Research (AACR) to be ... CA. These posters are related to multiple oncology,programs ...
Cached Medicine Technology:MIV Therapeutics Announces Pivotal Test Results Further Validating,Company Stent Coatings Meet Critical FDA Fatigue Guidelines 2MIV Therapeutics Announces Pivotal Test Results Further Validating,Company Stent Coatings Meet Critical FDA Fatigue Guidelines 3MIV Therapeutics Announces Pivotal Test Results Further Validating,Company Stent Coatings Meet Critical FDA Fatigue Guidelines 4Cytokinetics Announces Non-clinical Data to be Presented at the,2007 AACR Annual Meeting 2Cytokinetics Announces Non-clinical Data to be Presented at the,2007 AACR Annual Meeting 3Cytokinetics Announces Non-clinical Data to be Presented at the,2007 AACR Annual Meeting 4Cytokinetics Announces Non-clinical Data to be Presented at the,2007 AACR Annual Meeting 5Cytokinetics Announces Non-clinical Data to be Presented at the,2007 AACR Annual Meeting 6Cytokinetics Announces Non-clinical Data to be Presented at the,2007 AACR Annual Meeting 7
(Date:8/30/2014)... Hicksville, NY (PRWEB) August 30, 2014 ... Organizations throughout the planet has been one of ... in order to create a positive impact around ... aesthetics and staffed with top trained executives and ... millions of people worldwide. Vital statistics demonstrate ...
(Date:8/30/2014)... New York, New York (PRWEB) August 30, 2014 ... and other incretin mimetic claims continue to move forward ... a statement issued by AstraZeneca PLC on July 31, ... have been named in 409 product liability claims that ... cancer. Court documents indicate that many of these claims ...
(Date:8/30/2014)... AZ (PRWEB) August 30, 2014 Hastings ... personal injury attorneys located throughout Arizona is pleased to ... This is one specific example among many cases where ... clients are able to retain a greater portion of ... after case that providing a positive solution for Arizona ...
(Date:8/30/2014)... Serving contented clients since inception, #1 web ... is now offering discount for Labor Day on ... on putting forward the best of web development technology ... team of professionals and web developers and designers has ... the critical issues of web development and can develop ...
(Date:8/30/2014)... Bethesda, MD (PRWEB) August 30, 2014 In ... and increasingly difficult to get. Snoring and sleep apnea (a ... stops) robs people and their bed partners of the rest ... to 45% of the population snores and 20 million people ... only 10% have been diagnosed and treated; and of those ...
Breaking Medicine News(10 mins):Health News:Cradle of Aviation Museum Opens Its Doors to Long Island Scientologists 2Health News:Byetta Lawsuits Move Forward, as Bernstein Liebhard LLP Notes Settlements in More than 80 Cases 2Health News:Byetta Lawsuits Move Forward, as Bernstein Liebhard LLP Notes Settlements in More than 80 Cases 3Health News:Hastings and Hastings Is Pleased To Report Having Saved A Client $67,100 On A Settlement Of $610,000 2Health News:Profit By Outsourcing Offering Discount for Labor Day on all Web Development Services 2Health News:Snoring: Bad for Relationships, Bad for Health 2Health News:Snoring: Bad for Relationships, Bad for Health 3
... 12 Blue Cross of California,highly values the trust ... with their physicians and medical groups. It is,our responsibility ... to date,both for the benefit of our members and ... we do this is to send the member,s application ...
... ... New Event Name ... Same Commitment to ... the Health of all Babies, ... pleased to announce that 4-year-old Bradley,Coffey of Kennedy Heights and his family ... Formerly known as WalkAmerica,March for Babies is the March of Dimes premier ...
... Feb. 12 Echo Therapeutics,Inc. (OTC Bulletin Board: ... that it had completed an approximately,$2.3 million private ... VII, LLC and certain other select institutional and ... The $2,292,459 in aggregate principal amount of ...
... 12 Edwards Lifesciences,Corporation (NYSE: EW ), the ... that it has filed a patent infringement lawsuit against,CoreValve, ... Court for,the District of Delaware. The suit seeks injunctive ... family of patents for transcatheter,heart valve technology., "Edwards ...
... DARIEN, Ill., Feb. 12 Darien, IL-based Healthation,announced ... Provider Portal to deliver interactive self-service,capabilities to its ... track record of integrating with the plan,s existing ... claims directly through the,provider portal., The AboveHealth ...
... MENLO PARK, Calif., Feb. 12 XTENT, Inc.,(Nasdaq: ... results for 2007,after market close on Tuesday, February 19, ... day at 2 p.m., Pacific Time (5 p.m. Eastern ... XTENT,s President and Chief,Executive Officer, and Tim Kahlenberg, Chief ...
Cached Medicine News:Health News:Local Families Chosen for Ambassador Role for 2008 March for Babies 2Health News:Local Families Chosen for Ambassador Role for 2008 March for Babies 3Health News:Echo Therapeutics Announces Closing of Approximately $2.3 Million Private Financing 2Health News:Echo Therapeutics Announces Closing of Approximately $2.3 Million Private Financing 3Health News:Edwards Lifesciences Initiates Patent Infringement Litigation Against CoreValve in the U.S. 2Health News:PrimeWest Health Chooses Healthation's AboveHealth as Next Generation Provider Portal 2
An advanced microprocessor-controlled unit with superior reliability and reproducible power. Its modern electronics provides the precision and control a surgeon expects....
Compressor-cooled plate used to keep blocks cold while sectioning....
Compact instrument that quickly dries racks of slides using warm air....
Liquichek Blood Gas Plus EGL Control is an aqueous product used to monitor the measurement of pH, pCO2, pO2, electrolytes, glucose and lactate (lactic acid)....
Medicine Products: